Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 6/20 | 0.50 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.50 |
| ▸ | GNAO1 | P09471 | 5/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.50 |
| ▸ | CHRNB3 | Q05901 | 2/20 | 0.50 |
| ▸ | CHRNA6 | Q15825 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CHKA | P35790 | 1/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2578850 | 0.98 | GNAI3 (0.53) | GNAI3GNAI1GNAO1CHRNB2CHRNA3 | |
| SCHEMBL7976889 | 0.92 | L3MBTL1 (0.52) | GNAI3GNAI1GNAO1CHRNB2CHRNA3 | |
| Hydrochloric Acid SCHEMBL23778449 | 0.91 | L3MBTL1 (0.50) | GNAI3GNAI1GNAO1CHRNB2CHRNA3 | |
| SCHEMBL10617306 | 0.88 | CHRNB2 (0.52) | GNAI3GNAI1GNAO1CHRNB2CHRNA3 | |
| SCHEMBL2998705 | 0.88 | L3MBTL1 (0.60) | GNAI3GNAI1GNAO1L3MBTL1MEN1 | |
| SCHEMBL1073791 | 0.86 | L3MBTL1 (0.69) | GNAI3GNAI1GNAO1L3MBTL1MEN1 | |
| SCHEMBL6536788 | 0.84 | GNAI3 (0.69) | GNAI3GNAI1GNAO1L3MBTL1MEN1 | |
| SCHEMBL3601270 | 0.84 | GNAI3 (0.69) | GNAI3GNAI1GNAO1L3MBTL1MEN1 | |
| SCHEMBL8973060 | 0.84 | GNAI3 (0.69) | GNAI3GNAI1GNAO1L3MBTL1MEN1 | |
| SCHEMBL23533349 | 0.84 | GNAI3 (0.69) | GNAI3GNAI1GNAO1L3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108752277-A | A kind of 1-（3- methyl-1s-phenyl -1H- pyrazoles -5- bases）The safe preparation method of piperazine | 浙江理工大学 | 2018-11-06 | — | — | CN | claimed |
| US-8530650-B2 | 2, 5-diamino-substituted pyrido [4, 3-D] pyrimidines as autotaxin inhibitors against cancer | MERCK PATENT GMBH (DE) | 2013-09-10 | — | — | US | claimed |
| EP-2352732-B1 | 2,5-DIAMINO-SUBSTITUTED PYRIDO[4, 3-d]PYRIMIDINES AS AUTOTAXIN INHIBITORS AGAINST CANCER | MERCK PATENT GMBH (DE) | 2013-02-20 | — | — | EP | claimed |
| US-20110237583-A1 | 2, 5-DIAMINO-SUBSTITUTED PYRIDO [4, 3-D] PYRIMIDINES AS AUTOTAXIN INHIBITORS AGAINST CANCER | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG | 2011-09-29 | — | — | US | claimed |
| WO-2024026260-A1 | SUBSTITUTED IMIDAZOPYRAZINE COMPOUNDS AS IRAK3 BINDERS | CELGENE CORPORATION (US) | 2024-02-01 | — | — | WO | disclosed |
| EP-3983404-B1 | DISUBSTITUTED PYRAZOLE COMPOUNDS AS KETOHEXOKINASE INHBITORS | LILLY CO ELI (US) | 2023-08-09 | — | — | EP | disclosed |
| CN-112424171-B | Method for synthesizing sitagliptin and intermediate thereof through biocatalysis | 北京富盛嘉华医药科技有限公司 | 2023-02-28 | — | — | CN | disclosed |
| US-11459549-B2 | Method for biocatalytic synthesis of Sitagliptin and intermediate thereof | CHINA FORTUNE WAY COMPANY (CN) | 2022-10-04 | — | — | US | disclosed |
| WO-2022148821-A1 | USP7 BINDING SURVIVAL-TARGETING CHIMERIC (SURTAC) MOLECULES & USES THEREOF | LOCKI THERAPEUTICS LIMITED (GB) | 2022-07-14 | — | — | WO | disclosed |
| CN-113214102-A | Amine-containing transfection reagents and methods of making and using same | 生命技术公司 | 2021-08-06 | — | — | CN | disclosed |
| CN-113179590-A | Etching solution, replenishment solution, and method for forming copper wiring | MEC股份有限公司 | 2021-07-27 | — | — | CN | disclosed |
| EP-3831841-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T Global Inc. (US) | 2021-06-09 | — | — | EP | disclosed |
| EP-1748044-A1 | THIAZOLE COMPOUND AND USE THEREOF | Otsuka Pharmaceutical Company, Limited (JP) | 2007-01-31 | — | — | EP | disclosed |
| US-20050070559-A1 | Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3 | ASTRAZENECA AB (SE) | 2005-03-31 | — | — | US | disclosed |
| EP-1458394-A1 | USE OF OXINDOLE DERIVATIVES IN THE TREATMENT OF DEMENTIA RELATED DISEASES, ALZHEIMER S DISEASE AND CONDITIONS ASSOCIATED WITH GLYCOGEN SYNTHASE KINASE-3 | AstraZeneca AB (SE) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003055492-A1 | USE OF OXINDOLE DERIVATIVES IN THE TREATMENT OF DEMENTIA RELATED DISEASES, ALZHEIMER'S DISEASE AND CONDITIONS ASSOCIATED WITH GLYCOGEN SYNTHASE KINASE-3 | ASTRAZENECA AB (SE) | 2003-07-10 | — | — | WO | disclosed |
| EP-1214287-A1 | AMIDES AS INHIBITORS FOR PYRUVATE DEHYDROGENASE | AstraZeneca AB (SE) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001017942-A1 | AMIDES AS INHIBITORS FOR PYRUVATE DEHYDROGENASE | ASTRAZENECA AB (SE) | 2001-03-15 | — | — | WO | disclosed |
| CN-1056842-C | Amino acid derivative having anti CCK activity | TOBISHI PHARMACEUTICAL CO (JP) | 2000-09-27 | — | — | CN | disclosed |
| US-5773186-A | CONTAINING DIAZO COMPOUND AND A COUPLER | FUJI PHOTO FILM CO., LTD. (JP) | 1998-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070559-A1 | Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3 | GSK3A, GSK3B, PYGB | GNAI3 423/4885GNAI1 703/4885GNAO1 601/4885 |
| US-20110237583-A1 | 2, 5-DIAMINO-SUBSTITUTED PYRIDO [4, 3-D] PYRIMIDINES AS AUTOTAXIN INHIBITORS AGAINST CANCER | ENPP2, PLA2G4A, PLA2G4B | GNAI3 1577/4885GNAI1 1416/4885GNAO1 1123/4885 |
| US-11459549-B2 | Method for biocatalytic synthesis of Sitagliptin and intermediate thereof | DPP4, SI, DPP9 | GNAI3 3589/4885GNAI1 3734/4885GNAO1 3609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.